1st exclusively focused public neuroprotection company formed through the merger of IGT Pharma Inc and NTB Neurotrophic Bioscience Inc.
TORONTO, Oct. 26 /PRNewswire/ - NTB Neurotrophic Bioscience Inc. (``NTB'') and IGT Pharma Inc., are pleased to announce that they have entered into a Letter of Intent to merge. The combination of their respective programs in brain cell rescue will create the foundation for a critical mass of people, capital, proprietary libraries and candidate molecules. The combination of the two companies is a ``merger of equals'' transaction whereby IGT Pharma will acquire all of the issued and outstanding shares of NTB to create a new entity, to be renamed in a name to be determined, for purposes herein, ``CombinationCo'', subject to approval by the shareholders of both IGT Pharma and NTB, and acceptance by the Canadian Venture Exchange (``CDNX''). NTB is a Toronto based, private neuroscience company focused on the discovery and development of human therapeutics that will rescue brain cells from neuro- degenerative diseases such as Parkinson's. IGT Pharma and NTB are companies with highly complementary technology, products and corporate development priorities specifically relating to neuroprotection and neuronal subtype specificity. NTB is developing a highly sophisticated approach to the treatment of Parkinson's Disease (PD), Alzheimer's Disease (AD) and Amyotrophic Lateral Sclerosis (ALS).
biz.yahoo.com
Jim |
